Medivir is developing alovudine, an anti-HIV compound for the potential treatment of drug-resistant HIV infection. A phase IIa trial involving patients with multiresistant HIV was initiated in October 2001 and by July 2002, the trial had been completed.
Alovudine Medivir / S. Rusconi. - In: CURRENT OPINION IN INVESTIGATIONAL DRUGS. - ISSN 1472-4472. - 4:2(2003 Feb), pp. 219-23-223.
Alovudine Medivir
S. RusconiPrimo
2003
Abstract
Medivir is developing alovudine, an anti-HIV compound for the potential treatment of drug-resistant HIV infection. A phase IIa trial involving patients with multiresistant HIV was initiated in October 2001 and by July 2002, the trial had been completed.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
